PARP1 and neoplasm: The patient participated in a clinical trial for SOMCL-9112 (PARP1 inhibitor) for 4 courses in August 2018 at Shanghai Cancer Hospital, and stopped taking this medication due to tumor propagation and severe myelosuppression.